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Abstract: Multidose drug dispensing (MDD) is an adherence aid used by one-third of patients receiv-
ing home care services in Norway. The system can increase patient safety by reducing dispensing
errors and increase adherence, however it has also been criticised for unclear routines and distribution
of responsibilities. We investigated prescription problems which pharmacists have detected, and
the responsibilities they adopt regarding MDD. For two consecutive weeks, 11 pharmacies used
a self-completion form to register prescription problems identified with MDD. Of the 4121 MDD
prescriptions, problems were identified on 424 (11%). The most common issues were expired pre-
scriptions (29%), drug shortages (19%), missing prescriber signatures (10%) and unclear/missing
medication names or strengths (10%). Compared to ordinary prescriptions, the pharmacist took on
additional responsibility for renewing MDD prescriptions. However, because these patients received
their medications via the home care service, there was limited patient counselling during dispensing.
To increase the efficiency and patient safety of the MDD system, the roles and responsibilities of the
pharmacist, GP, and home care nurses in the MDD system should be clearly defined. This seems
most urgent for the renewal of prescriptions and patient counselling, where the responsibilities and
work practice seem to differ from ordinary prescriptions.
Keywords: multidose drug dispensing; prescribing errors; pharmacy practice; pharmacist interven-
tions; Norway
1. Introduction
Prescribing errors commonly cause preventable medication errors and adverse drug
events in primary care, many of which can lead to patient harm [1–3]. Pharmacists increase
medication safety by resolving prescription errors and other prescription problems, such
as drug shortages, issues with reimbursement, and drug–drug interactions [4–8]. Most
studies from primary care show that pharmacists intervene on 0.5–9% of prescriptions
dispensed [8–11], but some show frequencies up to 50% [9,12]. The great variation in these
rates is probably due to differences in the definitions of pharmacist’s intervention and in
the methods used to register them.
Previous studies of prescription interventions have not included prescriptions for
multidose drug dispensing (MDD). MDD, which is used by one third of patients receiving
home care services in Norway [13,14], is an adherence aid where the patients’ medications
are machine-dispensed in disposable plastic bags, usually for 14 days at a time. MDD is
believed to increase medication safety by reducing dispensing errors, reducing discrep-
ancies between medication lists, and increasing adherence [15–19]. However, researchers
have raised concerns that the MDD system increases the risk of inappropriate prescribing
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and medication errors, due to the automation of prescribing procedures and insufficient
routines for updating the MDD prescriptions [20–23].
The same laws apply to MDD and ordinary prescriptions, but there are some prac-
tical differences between the two prescription types. In Norway, over 90% of ordinary
prescriptions are issued electronically [24], while MDD prescriptions are paper-based and
faxed to the pharmacy. In addition, MDD prescriptions are often printouts from a GP’s
medical journal and contain a complete list of the patients’ medications, including regular
medications, as needed medications, and dietary supplements. This differs from ordinary
electronic prescriptions, where a prescription consists of only one item at a time. The only
legal difference between the two prescriptions is the timing of the pharmacist’s check [25].
For ordinary prescriptions, the pharmacist checks the prescription at each dispensing,
usually every three months for repeat prescriptions, while the MDD prescription is only
checked when there are changes in the patient’s medication treatment.
Regardless of prescription type, the pharmacist’s checks ensure that the medication,
dosage form, and the dose prescribed is in accordance with the patient’s age, gender
and indication written on the prescription. The pharmacist also checks for interactions,
contraindications, and other available information about the patient. In addition, the
validity of the prescription, including the prescriber’s identity and right to prescribe
medications is checked. Lastly, the pharmacist assesses whether the prescription label is
clearly written and whether the patient needs any additional information [25,26]. If the
prescription is incomplete, unclear or contains other problems, the pharmacist should try to
correct the error and intervene. If this is not possible, an emergency refill can be dispensed
if the pharmacist deems it necessary to prevent gaps in treatment and patient harm [25].
Most problems with the prescriptions are identified during the pharmacy check, how-
ever, the pharmacist’s ability to detect and resolve problems on prescriptions is affected by
factors such as patient age, care-setting, types of prescriptions and pharmacy [5,8–10,27–31].
Given the differences in format and routines for dispensing MDD and ordinary prescrip-
tions, it is likely that the pharmacist’s intervention rates vary between these two pre-
scription types. Despite the MDD system being criticised for its vague distribution of
responsibility and unclear routines across professional borders [17,32–34], no previous
studies have investigated the pharmacist’s responsibilities in the MDD system.
This study investigates: (1) the prescription problems in which pharmacists intervene;
and (2) the responsibilities they adopt while dispensing MDD prescriptions in Norwegian
community pharmacies.
2. Materials and Methods
2.1. The Development and Testing of the Registration Form
This cross-sectional study provides a descriptive analysis of prescription problems and
pharmacist interventions on MDD prescriptions. The term “prescription problem” refers to
errors, ambiguities, omissions, or other problems with the prescription that are potentially
harmful to patients or interfere with the dispensing process. “Pharmacist intervention”
refers to any action the pharmacist takes to resolve these prescription problems.
Based on a form used on ordinary prescriptions in previous studies [4,30], we devel-
oped a self-completion form for the registration of interventions on MDD prescriptions
(See Supplementary Table S1). Prescription problems were grouped as either formal or
medication-related (see Table 1) or relating to the MDD order (data not presented in this
study). Information about the patient, prescription, interventions, the outcomes of the
interventions and time spent on correcting errors were also recorded.
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Table 1. Prescription problems detected (n = 464), and the result of pharmacist interventions on multidose drug dispensing
(MDD) prescriptions.
Result of Intervention















104 (77%) 16 (12%) 2 (1%) 13 (10%) 135 (100%) 29%
Medication name
or strength 42 1 2 0 45 (33%) 10%
Dose or schedule 37 2 0 2 41 (30%) 9%
Drug–drug
interaction 9 9 0 2 20 (15%) 4%
Administration
formula 7 0 0 0 7 (5%) 2%
Treatment
duration 6 1 0 0 7 (5%) 2%




93 (39%) 131 (54%) 8 (3%) 9 (4%) 241 (100%) 52%
Prescription date




39 1 7 1 48 (20%) 10%
Reimbursement 22 1 0 1 24 (10%) 5%
Missing
prescriber data 9 0 0 2 11 (5%) 2%
Missing patient
data 8 0 0 0 8 (3%) 2%
Other 7 4 1 5 17 (7%) 4%
Drug shortages 52 (59%) 21 (24%) 13 (15%) 2 (2%) 88 (100%) 19%
TOTAL 249 (54%) 168 (36%) 23 (5%) 24 (5%) 464 (100%) 100%
A teaching manual including examples of common prescription problems and com-
pleted forms was developed. These were piloted on 100 prescriptions in one pharmacy
in 2017. The pilot provided important input to the design and content of the form and
teaching manual. The pilot interventions are not included in this study. The first three phar-
macies in this study provided feedback that led to minor adjustments in the self-completion
form, which were used in the eight consecutive pharmacies.
2.2. Selection of Pharmacies
At the time of our study, one pharmacy chain dispensed 80% of all MDD prescriptions
in Norway. We asked this pharmacy chain for a list of pharmacies with ≥500 MDD patients.
This cut-off was set to obtain a reasonable number of interventions per pharmacy. About
12% of MDD patients have changes in their drug regimen between MDD orders [35],
therefore 500 MDD patients equalled approximately 60 MDD prescription checks per
week. The pharmacy chain provided a list of 35 pharmacies. We purposefully selected
20 pharmacies and invited them by email to participate in our study. We aimed to obtain
a variety of geographical representation and workloads in terms of the number of MDD
prescriptions dispensed.
Pharmacy 2021, 9, 13 4 of 10
2.3. Data Collection
The study was conducted from February to October 2018. Each pharmacy collected
data for two consecutive weeks. We chose this time frame because most MDD bags last
for two weeks, which means that the pharmacy will order a new delivery of MDD for
all their patients within this period. To leave time for adjustments to the self-completion
form between the periods, no two pharmacies collected data during the same weeks.
Once a pharmacy accepted the invitation, a date for participation was allocated and the
teaching manual and self-completion form were emailed to the pharmacy. A week before
participation, we contacted the pharmacy to check whether the participants had read the
teaching manual and we answered any questions they had about the study.
Using the self-completion form, the participants registered all prescription problems
and interventions on MDD prescriptions for two consecutive weeks. The forms were sent
back to the researchers by post. The pharmacy chain extracted the total number of MDD
prescriptions dispensed from each pharmacy from their central dispensing database. We
defined the number of prescriptions as the number of pharmacist prescription checks. This
corresponds to the number of patients having changes in their medication treatment during
the study period.
The data were analysed in Microsoft Excel 2016. No personally identifiable informa-
tion was recorded, and thus the study did not require approval from the Regional Ethics
Committee.
3. Results
Of the 20 pharmacies invited to participate, 11 accepted. The main reason for declin-
ing was a lack of time or resources. The participating pharmacies were located in 9 of
the 11 counties in Norway, and dispensed between 47 and 1813 MDD prescriptions per
week, with a median of 109. In total, the pharmacists intervened on 464 prescriptions, an
intervention rate of 11.3% of all MDD prescriptions (n = 4121). The intervention rate varied
from 2.2% to 38.2% between the participating pharmacies.
As shown in Table 1, half of the interventions were related to formal problems with
the prescription, about one-third to medication issues, and one-fifth to drug shortages.
On average, the medication-related problems took 8.0 min to correct, drug shortages took
4.5 min and formal prescription problems took 3.6 min. Problems related to drug shortages
varied from 0 to 55% of the problems detected in each pharmacy.
Missing or unclear information about medication names, strengths, doses, or schedules
accounted for more than half of the medication-related prescription problems, in which
the majority were corrected or clarified before dispensing. Table 2 shows that a patient’s
medication history was the most common reason for the pharmacist to intervene on a
prescription, followed by computer-generated warnings and conflicting information about
the patient’s medication use from different sources (e.g., prescriptions from other doctors
than the GP, discharge notes from hospitals, messages from home care services, etc.).
Table 1 illustrates that over 70% of the formal prescription problems were due to
expired prescriptions or missing prescriber signatures. In addition, the prescribers were
contacted regarding 42 prescriptions that were about to expire (data not shown). For the
majority of formal prescription problems, the pharmacist did not obtain a valid prescription
before sending the MDD order and, therefore, dispensed void prescriptions.
In total, 88% of the problems were resolved by a pharmacist and the remaining by
pharmacy technicians. For 55% of the prescription problems, the pharmacist contacted the
prescriber to resolve the problem; for 17%, the home care services were contacted; and for
another 17%, the pharmacist used their professional judgment to resolve the problem.
Based on the problems detected and actions taken by the pharmacist, we have iden-
tified five different responsibilities the pharmacist adopts while dispensing MDD pre-
scriptions: checking prescriptions for clinical appropriateness, verifying the validity of
prescriptions, renewing prescriptions, patient counselling, and dispensing emergency
refills.
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Table 2. The five most frequent reasons for pharmacist intervention on medication-related problems on MDD prescriptions.
Reason for Intervention Examples of Prescription Problems n (%)
Patient medication history
The new prescription stated candesartan 32 mg, while the
previous prescription was 8 mg. The pharmacist reacted to
the sudden change in dose.
The patient had used methylphenidate 54 + 36 mg daily, but
the medication was missing on the new prescription. The
pharmacist wondered if the stop was intentional.
21 (16%)
Computer-generated warnings (drug–drug interactions)
Iron tablets and calcium were prescribed to the same patient
at the same time of day. Calcium reduces the absorption of
iron, and these should be taken 2–3 h apart from each other.
A patient started escitalopram while he was already using
dabigatran. This increases the chances of bleeding.
20 (15%)
Multiple sources with conflicting information about the
prescribed medicines
On the paper-based MDD prescription, ticagrelor was
prescribed as 90 mg, one tablet daily. On an ordinary
electronic prescription, the dosing schedule was 90 mg, two
times daily. The pharmacist wondered which dose the
patient should have.
Discharge notes from the hospital stated a temporary
reduction in the dose of apixaban. On the MDD prescription
from the GP, the treatment of apixaban was stopped. It was
unclear which of the prescriptions were the newest/correct.
18 (13%)
Incomplete prescriptions (due to handwriting)
A patient was prescribed valsartan, one tablet daily. No
strength was given.




A patient was prescribed a high dose of prednisolone in
MDD without a stop date. The pharmacist called to check if
there should be a tapering schedule.
A prescription contained two different dosing schedules for




One in nine of all MDD prescriptions needs an intervention or clarification by the
pharmacist before dispensing. The most common prescription problems were expired
prescriptions (27% of all problems), drug shortages (19%), and missing signatures (13%).
For most of the medication-related problems, the pharmacist clarified or corrected the
problem before dispensing. For the majority of formal prescription problems, the pharma-
cist reported dispensing MDD despite the prescription being invalid. Five percent of the
prescription problems resulted in one or more medications not being dispensed.
To our knowledge, our study is the first to specifically investigate prescription prob-
lems on MDD prescriptions. A Danish study reported errors on MDD prescriptions as a
part of a larger study and found an intervention rate of 0.85% [11]. This is considerably
lower than our findings, but this is expected due to the differences in definitions of an
MDD prescription. We have used the number of pharmacist checks (i.e., whenever there
are changes on a prescription), while the Danish study used the number of MDD orders
(i.e., one prescription every two weeks for each patient).
A prescription intervention rate of 11.3% is high compared to studies in community
pharmacies, which usually show interventions on 0.5–9.0% of prescriptions [8–11]. For
MDD prescriptions, the pharmacist usually has more information about the patients,
including a complete medication list and the indication for use. This could contribute
to a higher intervention rate [5,31]. Some evidence also suggests that intervention rates
are higher on new prescriptions than repeat prescriptions [8,30,36]. We have used the
number of pharmacist checks (i.e., whenever there are changes in the drug treatment) as
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the number of prescriptions dispensed, which might also explain our high intervention
rate. On the other hand, the pharmacist has less contact with the patients when supplying
MDD prescriptions, which could contribute to a lower intervention rate [4,5,27,30,37].
4.2. The Pharmacist’s Responsibilities
4.2.1. Checking Prescriptions for Clinical Appropriateness
The medication-related problems in our study constituted 29% of all problems; 3.3%
of the total MDD prescriptions. In comparison, clinically relevant interventions are done
on fewer than 1% of ordinary prescriptions [5–7,9,11,12,30,31]. “Medication-related inter-
ventions” is a broader definition than “clinically relevant interventions”, therefore it is
expected that our rate is higher than what is shown in these studies. The types of prob-
lems detected are similar to other studies, where missing or unclear information about
the medication name, strength, dose, or dosing schedule are among the most common
problems [4,5,7,11,28,30].
In our study, the pharmacist identified certain problems which would be difficult to
detect on ordinary prescriptions. When checking new MDD prescriptions, the pharmacist
compares this with the previous MDD medication list. This enables the pharmacist to
identify problems such as a sudden stop in medication treatment. In our study, 15% of the
medication-related problems were identified using the patients’ medication histories in
this way. We also discovered that 13% of the medication-related problems were revealed
because the pharmacist had access to different prescriptions with inconsistent information
about the patient’s current treatment. On ordinary prescriptions, the pharmacist rarely has
access to other information about the patient, apart from the electronic prescriptions they
are dispensing.
4.2.2. Verifying the Validity of Prescriptions
The majority of prescription problems detected in our study were related to formal
errors, in line with other studies regarding paper-based prescriptions [4,7,10,28,30]. Patient
and prescriber data are fields that must be completed to enter prescriptions into the
dispensing program, but this is not the case for a missing signature. The frequent detection
of this problem indicates that the pharmacists actively check the validity of the MDD
prescriptions before dispensing, and do not just detect the problems that physically hinder
the dispensing.
4.2.3. Renewing Prescriptions
Most prescriptions for regular medications are valid for one year, including MDD
prescriptions. Normally, the patient contacts the GP to renew prescriptions when they
are about to expire, but for MDD patients the home care service has this responsibility.
However, as our study shows, the pharmacist partly takes on this responsibility. Informing
that a prescription was expired (n = 125) or about to expire (n = 43) was the single most
common cause of the pharmacist contacting the prescriber. It seems to have become a com-
mon practice for many pharmacies to contact the GPs directly to renew MDD prescriptions
to prevent unintentional gaps in drug treatment [17].
4.2.4. Counselling Patients on the Use of Prescription Medications
The pharmacists should assess whether the prescription label is clearly written and
whether the patient needs any additional information about their medications [26]. The
MDD bags contain more information than medication labels, therefore this might reduce
the need for clarifying complex medication regimens, such as informing that medications
should be taken some hours apart or at specific times of the day.
However, assessing the patient’s need for information is more difficult in the MDD
system than for ordinary prescriptions, because the pharmacist has no direct contact
with the patient. Any medication counselling has to be conducted via the home care
services. When dispensing ordinary prescriptions, contact with the patient or caregiver
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can resolve up to half of the prescription-related problems [4,5,30,37]. Contact with the
home care nurses resolved only 17% of the problems in our study, while the majority were
resolved by contacting the GP. Our study indicates that the pharmacists only take limited
responsibility for patient counselling when supplying MDD prescriptions. Reduced patient
counselling about prescription medications upon dispensing might explain why patients
using MDD have less knowledge about their medications than patients with ordinary
prescriptions [16,18].
4.2.5. Dispensing Emergency Refills
Although the pharmacist frequently intervened on formal prescription problems, only
40% of these problems were corrected before dispensing, while 54% were dispensed despite
the prescription being invalid. Previous studies also show that for formal errors, the major-
ity of prescriptions were dispensed as prescribed [4,30]. However, the problems detected
in these studies were mostly reimbursement issues and missing patient information, which
were not errors that made the prescriptions invalid.
We have not investigated why the rate of dispensing invalid prescriptions is so high
in our study; however, there are some important differences between the MDD system
and ordinary prescriptions that might explain this finding. Stopping an MDD prescrip-
tion involves stopping all medications distributed in MDD, not just a single medication.
Secondly, MDD patients usually only have a few days of medication supply left when the
new MDD order is placed. The MDD bags have to be produced and shipped before the
patient receives them, therefore this leaves the pharmacist with less time to correct errors
and omissions on the prescriptions before the patient runs out of the medications. These
factors might raise the pharmacist’s threshold of stopping the dispensing.
According to legislation, a pharmacist can dispense an emergency refill only once
per prescription, and only in amounts necessary until the prescriber can be reached and
the error corrected [25]. If the emergency refill is only performed once for 14 days, this
can prevent patient harm because it prevents gaps in the patient’s regular medications.
However, if this practice is continued for longer periods, it might ultimately reduce patient
safety due to the patient not receiving regular medication reviews. If dispensing emergency
refills is a common practice, this might also explain why MDD users seem to have fewer
changes in their medication treatment than patients with ordinary prescriptions [20].
4.3. Implications and Suggestions for Improvement
This study shows that pharmacists play an important role in detecting and resolving
problems in MDD prescriptions. The pharmacist’s responsibility and practice for checking
clinical appropriateness and the validity of prescriptions seems to be similar for ordinary
prescriptions and MDD prescriptions. However, one can speculate whether the pharmacist
should have detected even more medication-related problems for these patients. MDD
patients, in general, use many medications, and potentially inappropriate medications are
common [20,38]. Pharmacists have access to the complete medication list for these patients;
this puts them in a position to review the medication treatment as a whole.
The pharmacist is responsible for counselling patients on the use of prescription medi-
cations; however, this seems to happen only to a limited degree for MDD patients. There
is no direct contact between the patient and the pharmacist upon dispensing, therefore
increasing the use of E-health technology, such as video consultations between the patient
and the pharmacist, could be considered. In the MDD system, the home care services
are also responsible for patient counselling [39]. To ensure that the patients receives the
information they need, the roles and responsibilities for patient counselling between these
professional groups should be more clearly defined.
We see that pharmacists frequently dispense emergency refills for MDD patients,
mostly due to prescriptions being expired. Additionally, pharmacists seem to have taken
on the additional responsibility of contacting GPs to renew prescriptions, a responsibility
which they do not take with ordinary prescriptions. This indicates that there is a lack
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of clear guidelines or enforcement of such guidelines when it comes to the renewal of
prescriptions in the MDD system. This highlights the need for clarifying the responsibility
of the GP, home care nurses and the pharmacist in this setting.
4.4. Strengths and Limitations of the Study
A strength in our study is that our registration form was based on those in previous
studies, and was piloted before the study. However, a self-completed form means that
problems might be underreported. Our selection of pharmacies is not representative for
MDD pharmacies in Norway, which means that there is uncertainty in the frequency of
different types of prescription problems. However, we feel that the purposeful selection
helped us capture the different types of problems which pharmacists identified. We
recruited pharmacies from all parts of the country, which increased the generalisability,
although there might have been a selection bias because many pharmacies declined to
participate. We were investigating routines for managing prescription problems, therefore
only having pharmacies from one of three chains is a limitation. However, we found a
great variation in both the number of problems detected and how they were solved, which
indicates that there is still variation in routines within the pharmacy chain. We also lack
the information of any clinical impact of the pharmacists’ interventions.
5. Conclusions
Community pharmacists contribute to safe and effective drug use by clarifying prob-
lems in one of every nine MDD prescriptions. One-third of the problems were related to
medications, half were formal errors with the prescriptions and the remaining problems
were related to drug shortages. As for ordinary prescriptions, the pharmacists check pre-
scriptions for clinical appropriateness, verify the validity of prescriptions, and dispense
emergency refills when deemed necessary. However, the pharmacists seem to take on
additional responsibilities for renewing prescriptions and counsel patients less than for
patients without MDD prescriptions. The responsibilities of the pharmacist differ between
ordinary prescriptions and MDD prescriptions, therefore there is a need for specific practice
guidelines for dispensing MDD prescriptions. Clearly defining the roles and responsibil-
ities of the pharmacist, GPs, and home care nurses, especially regarding the renewal of
prescriptions and patient counselling, has the potential to increase efficiency and patient
safety of the MDD system.
Supplementary Materials: The following are available online at https://www.mdpi.com/2226-478
7/9/1/13/s1, Table S1: A self-completion form for registering interventions on MDD prescriptions.
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